Publications by authors named "A Marfaing-Koka"
Background: It is not known if the endogenous surfactant pool available early in life is associated with the RDS clinical course in preterm neonates treated with CPAP. We aim to clarify the clinical factors affecting surfactant pool in preterm neonates and study its association with CPAP failure.
Methods: Prospective, pragmatic, blind, cohort study.
Objective: To determine the diagnostic accuracy of the surfactant adsorption test (SAT) as a predictor for the need for surfactant replacement therapy in neonates with respiratory distress syndrome (RDS).
Study Design: Amniotic fluid samples were collected from 41 preterm neonates with RDS treated with continuous positive airway pressure (CPAP) and 15 healthy control term neonates. Purified porcine surfactant served as a further control.
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Oncotarget
June 2016
Article Synopsis
- Tyrosine kinase inhibitors (TKIs) have significantly improved survival rates in chronic myeloid leukemia (CML) patients, particularly when molecular residual disease is undetectable.
- Despite deep molecular responses, BCR-ABL1-expressing leukemic stem cells (LSCs) were found to persist in some patients, raising concerns about the risk of relapse upon TKI therapy discontinuation.
- A study showed that LSCs were detectable in a minority of patients, and while TKI discontinuation led to rapid relapses in some, those who continued TKI therapy did not experience relapse, highlighting the challenges in managing CML.
In Schnitzler syndrome, which is mostly diagnosed with a low and asymptomatic monoclonal peak, anakinra has always exhibited a complete but only transient control of the auto-inflammatory signs, which are induced by interleukin (IL)-1 auto-activation. We focused on the treatment of a case of Schnitzler syndrome with moderate macroglobulinemia peak. Anakinra failed to improve the severe inflammatory anaemia and the dysglobulinemia, but rituximab-dexamethasone-cyclophosphamide chemotherapy alone allowed a complete response.
View Article and Find Full Text PDF